UniProt O75530
Polycomb protein EED (O75530)
Polycomb protein EED (UniProt O75530): 127 experimental structures and 1 predicted model on GenesisL1, 44 ligands bound, 240 pockets. Binding sites, druggability and experiment against prediction (TM-score) in GL1X.
- UniProt
- O75530
- Protein
- Polycomb protein EED
- Experimental structures
- 127
- Predicted models
- 1
- Ligands
- 44
- Pockets
- 240 · 34 records with a druggable one
Structures
128 records of O75530 in the MolNFT archive: 127 experimental, 1 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 3IIW | Crystal structure of Eed in complex with a trimethylated histone H3K27 peptide | x-ray diffraction | A | — | — |
| 3IIW | Crystal structure of eed in complex with a trimethylated histone H3K27 peptide | x-ray diffraction | A | — | — |
| 3IIY | Crystal structure of Eed in complex with a trimethylated histone H1K26 peptide | x-ray diffraction | A | — | — |
| 3IIY | Crystal structure of eed in complex with a trimethylated histone H1K26 peptide | x-ray diffraction | A | — | — |
| 3IJ0 | Crystal structure of Eed in complex with a trimethylated histone H3K9 peptide | x-ray diffraction | A | — | — |
| 3IJ0 | Crystal structure of eed in complex with a trimethylated histone H3K9 peptide | x-ray diffraction | A | — | — |
| 3IJ1 | Crystal structure of Eed in complex with a trimethylated histone H4K20 peptide | x-ray diffraction | A | — | — |
| 3IJ1 | Crystal structure of eed in complex with a trimethylated histone H4K20 peptide | x-ray diffraction | A | — | — |
| 3IJC | Crystal structure of Eed in complex with NDSB-195 | x-ray diffraction | A | — | — |
| 3IJC | Crystal structure of eed in complex with ndsb-195 | x-ray diffraction | A | — | — |
| 3JPX | EED: A Novel Histone Trimethyllysine Binder Within The EED-EZH2 Polycomb Complex | x-ray diffraction | A | — | — |
| 3JPX | Eed: a novel histone trimethyllysine binder within the eed-EZH2 polycomb complex | x-ray diffraction | A | — | — |
| 3JZG | Structure of EED in complex with H3K27me3 | x-ray diffraction | A | — | — |
| 3JZG | Structure of eed in complex with H3K27ME3 | x-ray diffraction | A | — | — |
| 3JZH | EED-H3K79me3 | x-ray diffraction | A | — | — |
| 3JZH | Eed-H3K79ME3 | x-ray diffraction | A | — | — |
| 3JZN | Structure of EED in apo form | x-ray diffraction | A | — | — |
| 3JZN | Structure of eed in apo form | x-ray diffraction | A | — | — |
| 3K26 | Complex structure of EED and trimethylated H3K4 | x-ray diffraction | A | — | — |
| 3K26 | Complex structure of eed and trimethylated H3K4 | x-ray diffraction | A | — | — |
| 3K27 | Complex structure of EED and trimethylated H3K9 | x-ray diffraction | A | — | — |
| 3K27 | Complex structure of eed and trimethylated H3K9 | x-ray diffraction | A | — | — |
| 4W2R | Structure of Hs/AcPRC2 in complex with 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin… | x-ray diffraction | E, F | — | — |
| 4W2R | Structure of HS/ACPRC2 in complex with 5,8-dichloro-2-[(4-methoxy-6… | x-ray diffraction | E, F | — | — |
| 4X3E | Crystal structure of EED in complex with a trimethylated Jarid2 peptide | x-ray diffraction | A | — | — |
| 4X3E | Crystal structure of eed in complex with a trimethylated JARID2 peptide | x-ray diffraction | A | — | — |
| 5GSA | EED in complex with an allosteric PRC2 inhibitor | x-ray diffraction | A, B | 73K | — |
| 5GSA | Eed in complex with an allosteric PRC2 inhibitor | x-ray diffraction | A, B | — | — |
| 5H13 | EED in complex with PRC2 allosteric inhibitor EED396 | x-ray diffraction | A | PR, LQA | 4 (best 0.77) |
| 5H13 | Eed in complex with PRC2 allosteric inhibitor EED396 | x-ray diffraction | A | — | — |
| 5H14 | EED in complex with an allosteric PRC2 inhibitor EED666 | x-ray diffraction | A, B | LQB | — |
| 5H14 | Eed in complex with an allosteric PRC2 inhibitor EED666 | x-ray diffraction | A, B | — | — |
| 5H15 | EED in complex with PRC2 allosteric inhibitor EED709 | x-ray diffraction | A, B | LQD | 8 (best 0.86) |
| 5H15 | Eed in complex with PRC2 allosteric inhibitor EED709 | x-ray diffraction | A, B | — | — |
| 5H17 | EED in complex with PRC2 allosteric inhibitor EED210 | x-ray diffraction | A | LQE | — |
| 5H17 | Eed in complex with PRC2 allosteric inhibitor EED210 | x-ray diffraction | A | — | — |
| 5H19 | EED in complex with PRC2 allosteric inhibitor EED162 | x-ray diffraction | A | LQF | — |
| 5H19 | Eed in complex with PRC2 allosteric inhibitor EED162 | x-ray diffraction | A | — | — |
| 5H24 | EED in complex with PRC2 allosteric inhibitor compound 8 | x-ray diffraction | A, B | LQG | — |
| 5H24 | Eed in complex with PRC2 allosteric inhibitor compound 8 | x-ray diffraction | A, B | — | — |
| 5H25 | EED in complex with PRC2 allosteric inhibitor compound 11 | x-ray diffraction | A, B | LQH | — |
| 5H25 | Eed in complex with PRC2 allosteric inhibitor compound 11 | x-ray diffraction | A, B | — | — |
| 5HYN | Structure of Human Polycomb Repressive Complex 2 (PRC2) with oncogenic histone H3K27M peptide | x-ray diffraction | B, G, L, R | — | 17 (best 0.87) |
| 5HYN | Structure of human polycomb repressive complex 2 (PRC2) with oncogenic histone H3K27M peptide | x-ray diffraction | B, G, L, R | — | — |
| 5IJ7 | Structure of Hs/AcPRC2 in complex with a pyridone inhibitor | x-ray diffraction | E, F | 6BN | — |
| 5IJ7 | Structure of HS/ACPRC2 in complex with a pyridone inhibitor | x-ray diffraction | E, F | — | — |
| 5IJ8 | Structure of the primary oncogenic mutant Y641N Hs/AcPRC2 in complex with a pyridone inhibitor | x-ray diffraction | E, F | 6BN | 12 (best 0.87) |
| 5IJ8 | Structure of the primary oncogenic mutant Y641N HS/ACPRC2 in complex with a pyridone inhibitor | x-ray diffraction | E, F | — | — |
| 5K0M | Targeting the PRC2 complex through a novel protein-protein interaction inhibitor of EED | x-ray diffraction | A | 6PU | 3 (best 0.77) |
| 5K0M | Targeting the PRC2 complex through a novel protein-protein interaction inhibitor of eed | x-ray diffraction | A | — | — |
| 5LS6 | Structure of Human Polycomb Repressive Complex 2 (PRC2) with inhibitor | x-ray diffraction | B, E, H, K | 74D | 16 (best 0.87) |
| 5LS6 | Structure of human polycomb repressive complex 2 (PRC2) with inhibitor | x-ray diffraction | B, E, H, K | 74D | — |
| 5TTW | Crystal Structure of EED in Complex with UNC4859 | x-ray diffraction | A, C | SO4, UNX | — |
| 5TTW | Crystal structure of eed in complex with UNC4859 | x-ray diffraction | A, C | SO4, UNX | — |
| 5U5H | Crystal structure of EED in complex with 6-(2-fluoro-5-methoxybenzyl)-1-isopropyl-5,6,7,8-tetrahydro… | x-ray diffraction | A | 7VV | 3 (best 0.77) |
| 5U5H | Crystal structure of eed in complex with 6-(2-fluoro-5-methoxybenzyl)… | x-ray diffraction | A | 7VV | — |
| 5U5K | Crystal structure of EED in complex with 3-(3-methoxybenzyl)piperidine hydrochloride | x-ray diffraction | A | 7VY | 4 (best 0.76) |
| 5U5K | Crystal structure of eed in complex with 3-(3-METHOXYBENZYL)PIPERIDINE hydrochloride | x-ray diffraction | A | 7VY | — |
| 5U5T | Crystal structure of EED in complex with H3K27Me3 peptide and… | x-ray diffraction | A, B | 7W7, YT3 | 6 (best 0.86) |
| 5U5T | Crystal structure of eed in complex with H3K27ME3 peptide and 3… | x-ray diffraction | A, B | 7W7, YT3 | — |
68 records more on the page itself.
Ligands
- L9W · N-(2,3-dihydro-1-benzofuran-4-ylmethyl)-8-(4-methylsulfonylphenyl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine · in 13 records
- CL · Chloride ion · in 6 records
- UNX · Unknown atom or ion · in 6 records
- EJR · N-[(5-fluoranyl-2,3-dihydro-1-benzofuran-4-yl)methyl]-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine · in 4 records
- YT3 · Yttrium (III) ion · in 4 records
- 73K · N-(furan-2-ylmethyl)-8-(4-methylsulfonylphenyl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine · in 3 records
- CA · Calcium ion · in 3 records
- LQD · (3R,4S)-1-[(2-methoxyphenyl)methyl]-N,N-dimethyl-4-(1-methylindol-3-yl)pyrrolidin-3-amine · in 3 records
- NA · Sodium ion · in 3 records
- 51A · N-[5-[(5-fluoranyl-2,3-dihydro-1-benzofuran-4-yl) methylamino]-[1,2,4]triazolo[4,3-c]pyrimidin-8-yl]benzamide · in 2 records
- 52R · N5-[(5-fluoranyl-2,3-dihydro-1-benzofuran-4-yl)methyl]-N8-methyl-N8-(1-methylpyrazol-3-yl)-[1,2,4]triazolo[4, 3-c]pyrimidine-5,8-diamine · in 2 records
- 54N · 8-[6-[(dimethylamino)methyl]-2-methyl-pyridin-3-yl]-5-[(5-fluoranyl-2,3-dihydro-1-benzofuran-4-yl) methylamino]-2H-pyrido[3,4-d]pyridazin-1-one · in 2 records
- 6BN · 5,8-dichloro-2-[(4-ethyl-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-({1-[(2R)-2-hydroxypropanoyl]piperidin-4-yl}oxy)-3,4-dihydroisoquinolin-1(2H)-one · in 2 records
- 74D · 1-[(1~{R})-1-[1-[2,2-bis(fluoranyl)propyl]piperidin-4-yl]ethyl]-~{N}-[(4-methoxy-6-methyl-2-oxidanylidene-3~{H}-pyridin-3-yl)methyl]-2-methyl-indole-3-carboxamide · in 2 records
- 7VV · (6S)-6-[(2-fluoro-5-methoxyphenyl)methyl]-1-(propan-2-yl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-3-amine · in 2 records
- 7VY · (3R)-3-[(3-methoxyphenyl)methyl]piperidine · in 2 records
- 7W7 · (3R)-3-[(2H-1,3-benzodioxol-4-yl)methyl]piperidine-1-carboximidamide · in 2 records
- 7WD · (6S)-6-[(2H-1,3-benzodioxol-4-yl)methyl]-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-3-amine · in 2 records
- 7XG · 2-[4-(4-{(3S,4R)-4-(dimethylamino)-1-[(2-fluoro-6-methylphenyl)methyl]pyrrolidin-3-yl}phenyl)-1H-pyrazol-1-yl]acetamide · in 2 records
- 82D · (3R,4S)-1-[(2-bromo-6-fluorophenyl)methyl]-N,N-dimethyl-4-(1-methyl-1H-indol-3-yl)pyrrolidin-3-amine · in 2 records
- EKF · N-(2,3-dihydro-1-benzofuran-4-ylmethyl)-8-[4-[(dimethylamino)methyl]phenyl]-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine · in 2 records
- EKR · N-(2,3-dihydro-1-benzofuran-7-ylmethyl)-8-[4-[(dimethylamino)methyl]phenyl]-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine · in 2 records
- L9T · N-(1,3-benzodioxol-4-ylmethyl)-4-methyl-5-(1-methylpyrazol-3-yl)-1,3-thiazol-2-amine · in 2 records
- MG · Magnesium ion · in 2 records
- Q3A · 8-(2,6-dimethylpyridin-3-yl)-N-[(5-fluoro-2,3-dihydro-1-benzofuran-4-yl)methyl]-1-(methylsulfonyl)imidazo[1, 5-c]pyrimidin-5-amine · in 2 records
- SO4 · Sulfate ion · in 2 records
- XB7 · 1-[(4-fluorophenyl)methyl]-N-{1-[2-(4-methoxyphenyl) ethyl]piperidin-4-yl}-1H-benzimidazol-2-amine · in 2 records
- ZMY · (9aP,12aR)-4-(2,2-difluoropropyl)-12-{[(5-fluoro-2,3-dihydro-1-benzofuran-4-yl)methyl]amino}-7-(trifluoromethyl)-4,5-dihydro-3H-2,4,8,11,12a-pentaazabenzo[4,5]cycloocta[1,2,3-cd]inden-3-one · in 2 records
- 6PU · (3R,4S)-1-[(1S)-7-fluoro-2,3-dihydro-1H-inden-1-yl]-N,N-dimethyl-4-{4-[4-(methylsulfonyl)piperazin-1-yl]phenyl}pyrrolidin-3-amine · in 1 record
- 82G · (3R,4S)-1-[(1S)-7-fluoro-2,3-dihydro-1H-inden-1-yl]-N, N-dimethyl-4-(1-methyl-1H-indol-3-yl)pyrrolidin-3-amine · in 1 record
Experiment against prediction
- 7QK4 chain A against the predicted model O75530: TM-score 1.00, RMSD 0.33 Å
- 7QK4 chain A against the predicted model O75530: TM-score 1.00, RMSD 0.33 Å
- 5U62 chain A against the predicted model O75530: TM-score 1.00, RMSD 0.35 Å
- 5U62 chain A against the predicted model O75530: TM-score 1.00, RMSD 0.35 Å
- 5U5T chain B against the predicted model O75530: TM-score 1.00, RMSD 0.36 Å
- 5U5T chain B against the predicted model O75530: TM-score 1.00, RMSD 0.36 Å
- 5U62 chain B against the predicted model O75530: TM-score 1.00, RMSD 0.37 Å
- 5U62 chain B against the predicted model O75530: TM-score 1.00, RMSD 0.37 Å
- 6SFC chain A against the predicted model O75530: TM-score 1.00, RMSD 0.37 Å
- 6SFC chain A against the predicted model O75530: TM-score 1.00, RMSD 0.37 Å
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.